CINECA IRIS Institutional Research Information System

DEL RE, MARZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.153
AS - Asia 6.188
EU - Europa 4.867
SA - Sud America 1.156
Continente sconosciuto - Info sul continente non disponibili 557
AF - Africa 374
OC - Oceania 24
AN - Antartide 1
Totale 26.320
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.789
SG - Singapore 2.118
IT - Italia 1.971
CN - Cina 1.508
HK - Hong Kong 1.068
BR - Brasile 932
SE - Svezia 635
VN - Vietnam 595
GB - Regno Unito 410
DE - Germania 407
BG - Bulgaria 302
FR - Francia 267
CA - Canada 213
FI - Finlandia 174
IN - India 163
CI - Costa d'Avorio 157
RU - Federazione Russa 157
JP - Giappone 150
TR - Turchia 133
AT - Austria 132
NL - Olanda 110
AR - Argentina 83
BD - Bangladesh 81
PL - Polonia 68
KR - Corea 63
SN - Senegal 61
MX - Messico 56
IQ - Iraq 50
ZA - Sudafrica 47
ES - Italia 46
ID - Indonesia 34
PK - Pakistan 32
UA - Ucraina 32
BE - Belgio 31
SA - Arabia Saudita 31
VE - Venezuela 31
EC - Ecuador 28
MA - Marocco 24
NG - Nigeria 23
UZ - Uzbekistan 23
CR - Costa Rica 22
CO - Colombia 21
LT - Lituania 19
AU - Australia 18
CH - Svizzera 17
KE - Kenya 16
JM - Giamaica 15
PH - Filippine 15
UY - Uruguay 15
CL - Cile 14
CZ - Repubblica Ceca 13
PY - Paraguay 13
RO - Romania 12
TW - Taiwan 12
IL - Israele 10
JO - Giordania 10
MY - Malesia 10
PE - Perù 10
TT - Trinidad e Tobago 10
EU - Europa 9
KZ - Kazakistan 9
NP - Nepal 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
IE - Irlanda 8
NI - Nicaragua 8
TN - Tunisia 8
AL - Albania 7
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
LB - Libano 7
PA - Panama 7
EG - Egitto 6
GT - Guatemala 6
LV - Lettonia 6
SV - El Salvador 6
TH - Thailandia 6
DK - Danimarca 5
ET - Etiopia 5
GR - Grecia 5
HN - Honduras 5
NO - Norvegia 5
PT - Portogallo 5
BJ - Benin 4
GH - Ghana 4
HR - Croazia 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NZ - Nuova Zelanda 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BF - Burkina Faso 3
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
GE - Georgia 3
KW - Kuwait 3
LU - Lussemburgo 3
Totale 25.727
Salva come PNG Salva come JPEG
Città #
Ashburn 1.464
Singapore 1.102
Hong Kong 1.050
Fairfield 906
Woodbridge 878
Dallas 874
Santa Clara 809
San Jose 693
Houston 623
Ann Arbor 584
Chandler 548
Serra 434
Shanghai 421
Seattle 402
Wilmington 320
New York 313
Sofia 300
Beijing 286
Council Bluffs 268
Boardman 266
Cambridge 264
London 244
Los Angeles 244
Florence 183
Pisa 179
Princeton 177
Ho Chi Minh City 165
Abidjan 157
Lawrence 148
Lauterbourg 141
Milan 129
Medford 122
Tokyo 122
Vienna 119
Ottawa 106
Hanoi 103
Munich 97
São Paulo 91
Frankfurt am Main 89
Hefei 88
Buffalo 83
Rome 72
Redondo Beach 69
Istanbul 68
Chicago 67
San Diego 67
Dearborn 62
Warsaw 62
Dakar 61
Des Moines 60
Nanjing 60
Helsinki 58
Dong Ket 52
Seoul 52
Turku 52
Turin 49
Rio de Janeiro 44
Phoenix 42
Bremen 39
Ogden 39
Nuremberg 37
Cascina 34
Montreal 34
Boulder 33
Toronto 32
Orem 30
Izmir 28
Redwood City 28
Da Nang 27
Brussels 24
Fuzhou 24
Kunming 24
Düsseldorf 23
Lagos 23
San Francisco 23
Paris 22
Washington 22
Brasília 21
Brooklyn 21
Denver 21
Tashkent 21
Chennai 20
Stockholm 20
Columbus 19
Guangzhou 19
Livorno 19
Nanchang 19
Naples 19
New Delhi 19
Baghdad 18
Changsha 18
Mumbai 18
Belo Horizonte 17
Johannesburg 17
Amsterdam 16
Hyderabad 16
Jacksonville 16
Mexico City 16
Quanzhou 16
Bologna 15
Totale 17.556
Salva come PNG Salva come JPEG
Nome #
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 454
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 336
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 308
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 254
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 223
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 216
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. 215
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 215
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 211
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 210
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 206
EGFR signaling pathway as therapeutic target in human cancers 205
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 204
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 204
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 203
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 203
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 196
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 195
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 194
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 193
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 193
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 191
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 189
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 188
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 187
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 187
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 187
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 184
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 184
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 184
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro 183
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 182
Clinical pharmacology of intravitreal anti-VEGF drugs 180
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence 180
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 180
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 180
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 179
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 178
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 177
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 176
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 176
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors 175
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 175
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 173
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial 173
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 172
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 172
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 171
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 170
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 169
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 166
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 165
Author's reply. 163
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 163
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment 162
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 162
Pharmacogenetics of anti-estrogen treatment of breast cancer 161
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 161
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 161
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 159
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 158
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 158
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant 156
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 156
Genome Wide Association Studies (GWAS) 155
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 155
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? 154
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 153
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 152
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 151
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. 151
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 151
Radiomics and liquid biopsy in oncology: the holons of systems medicine 150
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 150
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 150
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 149
Genetic variation: effect on prostate cancer 145
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 145
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 145
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 143
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 143
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 143
null 142
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 141
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 140
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 140
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 139
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 138
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients 136
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position 135
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 135
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 134
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 133
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 132
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 132
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? 132
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer 131
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 131
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele 130
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 129
Totale 17.406
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.450 0 0 22 36 237 269 95 74 100 96 93 428
2022/20232.415 299 323 170 170 193 287 33 156 499 25 230 30
2023/20241.704 99 112 263 81 171 327 96 73 40 85 142 215
2024/20255.838 94 205 69 256 579 649 466 333 630 732 645 1.180
2025/20267.315 498 918 907 953 707 514 1.035 334 396 572 314 167
2026/20271.112 223 501 388 0 0 0 0 0 0 0 0 0
Totale 26.320